Copy to clipboard 
Naitive Technologies announced a strategic agreement with Parvizi Surgical Innovation (PSI) to advance the development and clinical deployment of OsteoSight, technology designed for the early identification of low bone mineral density.
OsteoSight uses AI to opportunistically scan through millions of routine x-rays for evidence of low bone mineral density, an early warning sign of osteoporosis, and was granted FDA Breakthrough Device Designation last year. Supported by PSI’s expertise in research, product development and musculoskeletal care, this collaboration aims to expedite the validation and implementation of OsteoSight within clinical settings, making it more accessible to the millions of people with undiagnosed osteoporosis.
“Orthopedic surgeons are uniquely positioned to identify and address osteoporosis at an early stage, meaning more effective and accessible interventions for patients. We’re excited to collaborate with Naitive, whose commitment to integrating clinical user feedback into their technology development is evident, and by ensuring OsteoSight aligns with clinical workflows, they’re setting the standard in user-centered innovation,” said Dr. Javad Parvizi, Founder & CEO of PSI. “Our members include some of the world’s foremost orthopedic surgeons, and their expertise will be invaluable in ensuring OsteoSight delivers great clinical value and fits into the workflows of busy orthopedic practices.”
“Naitive has consistently demonstrated a commitment to advancing healthcare for both patients and providers through robust technology and sound business practices,” said Dr. Wael Barsoum, member of Parvizi Surgical Innovation and President of HOPCo. “Having collaborated with Naitive on several research initiatives in my role at HOPCo, I’ve seen firsthand the potential of OsteoSight and the value it can bring to musculoskeletal care. At PSI, we see a tremendous opportunity to enhance this technology and to improve patient outcomes.”
“We are delighted to partner with Parvizi Surgical Innovation, whose knowledge and network in orthopedic surgery will be invaluable as we move OsteoSight closer to clinical adoption,” said Dr. Will Briggs, CEO of Naitive. “With PSI’s support, we’re ensuring our technology meets the rigorous standards of clinical care but also seamlessly integrates into real-world orthopedic workflows. Their leadership in musculoskeletal care, combined with our breakthrough technology, will help us make significant advancements in the early diagnosis and treatment of osteoporosis.”
Source: Naitive
Naitive Technologies announced a strategic agreement with Parvizi Surgical Innovation (PSI) to advance the development and clinical deployment of OsteoSight, technology designed for the early identification of low bone mineral density.
OsteoSight uses AI to opportunistically scan through millions of routine x-rays for evidence of low bone...
Naitive Technologies announced a strategic agreement with Parvizi Surgical Innovation (PSI) to advance the development and clinical deployment of OsteoSight, technology designed for the early identification of low bone mineral density.
OsteoSight uses AI to opportunistically scan through millions of routine x-rays for evidence of low bone mineral density, an early warning sign of osteoporosis, and was granted FDA Breakthrough Device Designation last year. Supported by PSI’s expertise in research, product development and musculoskeletal care, this collaboration aims to expedite the validation and implementation of OsteoSight within clinical settings, making it more accessible to the millions of people with undiagnosed osteoporosis.
“Orthopedic surgeons are uniquely positioned to identify and address osteoporosis at an early stage, meaning more effective and accessible interventions for patients. We’re excited to collaborate with Naitive, whose commitment to integrating clinical user feedback into their technology development is evident, and by ensuring OsteoSight aligns with clinical workflows, they’re setting the standard in user-centered innovation,” said Dr. Javad Parvizi, Founder & CEO of PSI. “Our members include some of the world’s foremost orthopedic surgeons, and their expertise will be invaluable in ensuring OsteoSight delivers great clinical value and fits into the workflows of busy orthopedic practices.”
“Naitive has consistently demonstrated a commitment to advancing healthcare for both patients and providers through robust technology and sound business practices,” said Dr. Wael Barsoum, member of Parvizi Surgical Innovation and President of HOPCo. “Having collaborated with Naitive on several research initiatives in my role at HOPCo, I’ve seen firsthand the potential of OsteoSight and the value it can bring to musculoskeletal care. At PSI, we see a tremendous opportunity to enhance this technology and to improve patient outcomes.”
“We are delighted to partner with Parvizi Surgical Innovation, whose knowledge and network in orthopedic surgery will be invaluable as we move OsteoSight closer to clinical adoption,” said Dr. Will Briggs, CEO of Naitive. “With PSI’s support, we’re ensuring our technology meets the rigorous standards of clinical care but also seamlessly integrates into real-world orthopedic workflows. Their leadership in musculoskeletal care, combined with our breakthrough technology, will help us make significant advancements in the early diagnosis and treatment of osteoporosis.”
Source: Naitive
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
